RxDoctor Payments Data

Jeffrey Hancock, MD

Pediatrics · Rexburg, IDNPI 1265637573

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $18,220 of the $20,415 with a category attached, or 89.2%. It is spread thinly across 60 manufacturers, the largest accounting for just 7.1% — the pattern of someone who eats at a lot of different presentations. Among pediatrics clinicians in ID with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$20,415in general payments, 2019–2025

Across 1,130 payments — averaging $18.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • E.r. Squibb & Sons, L.L.C.$1K
  • Pfizer$1K
  • Varian Medical Systems, Inc.$1K
  • Merck$1K
  • Seagen Inc.$992
  • plus $13K from 54 others

What the payments were for

  • Consulting fees$1,1256%
  • Food & beverage$18,22089%
  • Education$1,0705%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca(2 entities)71$1,452
E.r. Squibb & Sons, L.L.C.97$1,266
Pfizer106$1,202
Varian Medical Systems, Inc.2$1,125
Merck57$1,019
Seagen Inc.44$992
Novartis64$987
Incyte Corporation38$858
Genentech USA, Inc.55$835
Amgen53$793
Sanofi44$733
Eisai Inc.42$700
Johnson & Johnson(2 entities)35$658
Daiichi Sankyo Inc.28$538
AbbVie27$509
Bristol Myers Squibb20$452
Bayer39$446
Takeda Pharmaceuticals U.S.A., Inc.16$392
Lilly USA, LLC21$377
Jazz Pharmaceuticals Inc.16$375
Astellas Pharma US Inc15$259
GSK15$252
Tersera Therapeutics LLC13$233
Gilead(2 entities)13$223
Pharmacyclics LLC, An Abbvie Company13$217
EMD Serono, Inc.11$217
CSL Behring12$200
AVEO Pharmaceuticals, Inc.5$161
Rigel Pharmaceuticals, Inc.10$161
Puma Biotechnology, Inc.8$150
Servier Pharmaceuticals LLC7$139
Boehringer Ingelheim7$139
Beone Medicines USA, Inc.4$123
Karyopharm Therapeutics Inc.6$115
Blueprint Medicines Corporation6$112
Beigene USA, Inc.6$105
Stemline Therapeutics Inc.5$101
Myovant Sciences Inc.6$99
Sumitomo Pharma America, Inc.5$97
EUSA Pharma (US) LLC5$92
Exelixis Inc.5$88
Genmab U.S., Inc.4$88
Dendreon Pharmaceuticals LLC4$88
Pharmacosmos Therapeutics Inc.5$88
Coherus Oncology, Inc.4$77
Clovis Oncology, Inc.4$68
Acrotech Biopharma Inc.4$66
Ipsen Biopharmaceuticals, Inc4$65
Sobi, Inc3$62
Pharmaessentia USA Corporation3$54
Fennec Pharmaceuticals, Inc.3$52
ADC Therapeutics America, Inc.2$40
Mirati Therapeutics, Inc.2$40
Adaptive Biotechnologies Corporation2$39
Springworks Therapeutics, Inc.2$39
Morphosys, US Inc.2$37
Immunocore Limited1$30
G1 Therapeutics, Inc.2$28
Iovance Biotherapeutics, Inc.1$26
Regeneron Healthcare Solutions, Inc.2$26

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$20,415 in reported general payments places this provider in the 95th percentile of 150 pediatrics providers in Idaho.

See all pediatrics providers in Idaho

Medicare billing

Part B allowed, 2024
$43,521
Medicare patients
168
Services billed
330

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Lenalidomide46$719,392
KoselugoSelumetinib Sulfate24$301,712
ImbruvicaIbrutinib14$227,629
EliquisApixaban53$42,767
VenclextaVenetoclax13$29,333
XareltoRivaroxaban31$22,869
Hydroxyurea37$1,100
Tamoxifen Citrate25$915
Cyanocobalamin InjectionCyanocobalamin (Vitamin B-12)11$652
Anastrozole29$495
Dexamethasone15$418
Levothyroxine Sodium29$404
Ondansetron OdtOndansetron21$241
Prednisone15$205
Celecoxib13$185

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaKoselugo$1,452$301,71224 claims
Pharmacyclics LLC, An Abbvie CompanyImbruvica$217$227,62914 claims
PfizerEliquis$1,202$42,76753 claims
AbbVieVenclexta$509$29,33313 claims
Johnson & JohnsonXarelto$658$22,86931 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 150 pediatrics providers in Idaho.

Other pediatrics in Rexburg

See the full list for Idaho

Where these figures come from

Is this you, or does something look wrong? →